The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Revelations of data manipulation might not be fatal, but they will hurt the chief exec’s attempted rebranding of Novartis as a more ethical pharma company.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
More data with voxelotor shouldn’t hurt the project’s bid for accelerated approval, but there are still doubts about its effect on a harder patient outcome.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Manufacturing issues prompt the US regulator to knock back projects from Nabriva and Heron Therapeutics, both of which insist that the problems are easily solvable.